Kessler Topaz Meltzer & Check, LLP Class Action Announcement GERN: A Securities Fraud Class Action Lawsuit Was Filed Against Geron Corporation (GERN)

Core Viewpoint - Securities class action lawsuits have been filed against Geron Corporation for allegedly misleading investors regarding its revenue outlook and product performance during the specified class period [1][3]. Group 1: Allegations Against Geron Corporation - Defendants allegedly created a false impression of possessing reliable information about Geron's revenue outlook while downplaying risks from seasonality and macroeconomic factors [3]. - Reports regarding the launch success and growth potential of Geron's primary product, RYTELO, were claimed to be overly optimistic and did not reflect the reality of market conditions [3]. - RYTELO reportedly lacked market penetration awareness, hindering Geron's ability to meet the unmet need for the drug among first-line patients and those outside academic settings [3]. - Statements made by the defendants about the company's business and prospects were claimed to be materially false and misleading [3]. Group 2: Legal Process for Investors - Geron investors can seek to be appointed as lead plaintiffs by May 12, 2025, through Kessler Topaz Meltzer & Check, LLP or other counsel [4]. - A lead plaintiff represents the interests of all class members and typically has the largest financial stake in the case [4]. - Investors can choose to remain absent class members without affecting their ability to share in any recovery [4].